ClinicalTrials.gg
Not yet recruitingNCT07844291SwithADCUpdated Sep 28, 2026

A Prospective, Open-label, Randomized Trial Comparing Switch to A1811 Versus Continued THP Neoadjuvant Therapy After THP Induction in HER2-Positive Breast Cancer

An interventional study of A1811 and THP in Breast Cancer (Early Breast Cancer), sponsored by Peking University People's Hospital. Not yet recruiting. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Peking University People's Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
432
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Breast Neoplasms by Peking University People's Hospital — 17 open to participants now, 18 under way, none of them phase 3. Breast Neoplasms · Peking University People's Hospital.

Planned enrollment
3rd of 17
432 · median 200
Started
2026
with 6 others
No phase
7 of 32
4 open now
Primary completion
2031-12
later than 16 of 17 live
Registered
31st of 32
by date

Among the 32 studies in Breast Neoplasms by Peking University People's Hospital, this one is the 3rd largest by planned enrollment of the 17 interventional ones that give a count, is one of 7 that started in 2026, is one of 7 with no phase, reaches primary completion later than 16 of the 17 other live ones, and was the 31st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 32 studies in Breast Neoplasms by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Breast Neoplasms by Peking University People's Hospital, or all of them as a file.
02

Study summary

This is a multicenter, open-label, randomized controlled trial. A total of 432 eligible patients with HER2-positive breast cancer will be enrolled after screening. All patients will receive THP-based neoadjuvant therapy (THP) for 2 cycles. After 2 cycles, imaging-based response will be assessed according to RECIST v1.1. Patients with a response or stable disease (PR or SD) will be randomized 1:1 into the experimental group or the control group. Randomization occurs after the 2-cycle assessment. Experimental group: Switch to A1811 therapy for 4 cycles. Control group: Continue the THP regimen for 4 cycles. After completing a total of 6 cycles of neoadjuvant therapy, all patients will undergo definitive surgical treatment for pathological assessment. Primary endpoint: Pathologic complete response (pCR).

03

Conditions studied

  • Breast Cancer (Early Breast Cancer)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- 1.18-75 years old 2. (ECOG) performance status of 0 or 1 3.-positive breast cancer was defined by core needle pathology showing HER2 positivity, with IHC score of 3+ or IHC score 2+ with positive ISH results 4.At initial diagnosis, tumors were stage II-III according to the AJCC 8th edition breast cancer staging system and deemed operable 5.no prior history of any systemic anti-cancer therapy for breast cancer 6.Adequate organ function 7.Women of must have a negative pregnancy test prior to enrollment. Women of must commit to using effective from study start until 6 months after the last dose of study medication, with ongoing assessment of adherence to contraception.

8.All participants must voluntarily participate in this study and provide written , with consent approved by the ethics committee prior to use

Exclusion criteria

Exclusion Criteria:

- 1.Bilateral breast cancer, stage IV breast cancer, or inflammatory breast cancer; 2.Any history of within 5 years prior to signing , excluding treated cervical carcinoma in situ, non-melanoma skin cancer (basal cell carcinoma or squamous cell carcinoma) in remission; 3.Receiving anti-tumor therapy in another interventional clinical trial concurrently, including but not limited to chemotherapy, endocrine therapy, biologic therapy, bone-modifying agents, or ; 4.Major surgery unrelated to breast cancer within 4 weeks prior to the first dose of study drug, or not yet fully recovered from such surgery; 5.Severe cardiac disease or unstable condition; 6.Uncontrolled active infections; history of immunodeficiency, including -positive status, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation 7. Known to any component of the study drug regimen; 8. Pregnant or breastfeeding women, women of with a positive baseline pregnancy test, or sexually active individuals not willing to use effective from the time of enrollment through 6 months after the last study drug administration; 9.Known or suspected interstitial pneumonia; major or pre-existing respiratory diseases within 3 months prior to first dose that could interfere with assessment of drug-related pulmonary toxicity or its management.

10.urrently participating in another interventional pharmacologic clinical study; 11. Refusal to comply with follow-up procedures; 12. Presence of other serious medical or psychiatric conditions or laboratory abnormalities that may increase the risk of participation, interfere with study results, or for any other reason lead the investigator to believe the subject is not suitable for participation in this study.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
432 participants (estimated)

Study arms

  • Experimental
    swithing to A1811

    Switch to A1811 therapy for 4 cycles

    Drug: A1811

  • Active comparator
    THP

    Continue the THP regimen for 4 cycles

    Drug: THP

Interventions

06

What researchers measure

Primary outcomes

  1. pCR

    After completion of neoadjuvant therapy, patients underwent definitive surgical resection; histopathological assessment of the hematoxylin and eosin-stained excised breast cancer specimens and all ipsilateral lymph node samples showed no residual invasive cancer.

    Time frame: From enrollment to the end of treatment at 6 months

Secondary outcomes

  1. ORR

    The proportion of subjects achieving CR or PR as the best tumor response during neoadjuvant therapy. The investigators will assess objective response rate (ORR) according to RECIST v1.1.

    Time frame: From enrollment to the end of treatment at 6 months

  2. EFS

    Time from randomization to the first occurrence of any of the following events: disease progression prior to surgery, local or distant recurrence after surgery, or death from any cause.

    Time frame: From enrollment to the end of treatment at 5 years

  3. OS

    he time from randomization to death from any cause.

    Time frame: From enrollment to the end of treatment at 5 years

  4. AE rate

    AEs were graded according to NCI-CTCAE v5.0. Descriptive statistics were summarized by treatment group for: any AE, AEs ≥ Grade 3, SAEs, drug-related AEs, drug-related SAEs, AEs leading to dose modification, and AEs leading to discontinuation of therapy. For each category, the number of patients with at least one event and the proportion (with 95% CI) of the corresponding total evaluable patients in each group were reported.

    Time frame: From enrollment to the end of treatment at 4 weeks

  5. RCB0/1

    Residual Cancer Burden (RCB) was calculated from the surgical specimen using the published MD Anderson RCB methodology, incorporating: (1) residual tumor bed size in the breast (cm), (2) invasive cancer cellularity (%), (3) in situ component (%), (4) number of positive axillary lymph nodes and the largest metastasis size (mm). The resulting continuous RCB index (0-11.9) was categorized into RCB classes (RCB I, II, III) according to established cutoffs. Calculations were performed using the MD Anderson RCB calculator or an equivalent validated implementation, with results reviewed by study pathologists

    Time frame: From enrollment to the end of treatment at 4 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2031, 61 months later.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 61 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 28, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Dec 31, 2031
CompletionEst.
Dec 31, 2031
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07844291
Responsible party
Shu Wang (chief, Peking University People's Hospital) — Principal investigator
First posted
Sep 28, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Sep 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion